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ABSTRACT
Background: Second generation antihistamines (SGAs) are approved to treat seasonal
and/or perennial allergic rhinitis (AR) and chronic idiopathic urticaria (CIU). It is
estimated that 82% of Americans with AR use antihistamines, with the majority using
SGAs due to their low side effect profile. As policy, over-the-counter (OTC) SGAs were
not covered in this health plan population (cetirizine and loratadine products were
available OTC prior to the study period, while fexofenadine products became available
OTC during the study period). On January 1, 2012, the policy was extended to remove
coverage of prescription-only SGAs (included desloratadine and levocetirizine products).
Objectives: To assess the utilization of SGAs and SGA alternatives and to assess the
rate of product switching associated with coverage changes.
Methods: Pharmacy claim data from January 1, 2010 to October 31, 2012 were analyzed
using the Truven Health Advantage Suite® system. Study participants had to be
continuously enrolled, ≥18 years, and have received ≥1 prescription for a desloratadine,
fexofenadine, or levocetirizine product during the study period. Three reference periods
were evaluated to assess utilization patterns: (1) a period during which desloratadine,
fexofenadine, and levocetirizine were covered; (2) a desloratadine and levocetirizine
prescription-only coverage period during which fexofenadine OTC was introduced to the
market; and (3) an SGA non-coverage period. Product switching was determined by
having at least one new fill for a covered SGA or SGA alternative after a coverage
change.
Results: 84.6% of health plan participants taking SGAs did not switch to a prescription
SGA alternative following SGA coverage discontinuation. For those who did switch, the
most common therapeutic class switched to was intranasal corticosteroids (54%), which
is the recommended first-line therapy for AR. More than half of the members who
switched to a prescription SGA alternative were not persistent in filling the new

medication, which could suggest that those members purchased an OTC SGA or left their
condition untreated.
Conclusion: The policy decision to discontinue coverage of SGAs was not associated
with seeking a prescription alternative by the majority of plan members. With the
potential for more medications to go OTC, this observational study illustrates that
managed care organizations can efficiently manage drug costs for a fixed population by
reserving scarce plan resources through appropriate benefit design management.
Keywords: antihistamines, product switching, coverage, utilization, OTC medications
What is already known about this subject


For the treatment of allergic rhinitis, prescription and over-the-counter (OTC)
products exist as options for the 58 million Americans impacted by the upper
respiratory condition, including second generation antihistamines (SGAs).



Intranasal corticosteroids have shown greater efficacy in trials, but SGAs continue
to be the most heavily utilized therapeutic class.



The decision not to cover prescription products within a therapeutic class that has
OTC products and the opportunity costs associated with such a decision are of
interest to payers and employers within the health insurance industry.

What this study adds


After drug coverage was removed for SGAs, increases in alternative prescription
products were minimal, and the majority of health plan participants either
purchased an OTC alternative or left the condition untreated.



The observed results from this study may be applicable to other health plans and
can be used for the decision-making process for plan sponsors.

Disclosure Statement
No funding was received for this study. The authors report no conflict of interest
regarding this study.
BACKGROUND
Second generation antihistamines (SGAs) are approved to treat seasonal and/or
perennial allergic rhinitis (AR) and chronic idiopathic urticaria (CIU).1 AR affects about
58 million Americans, which represents approximately 20% of the population.2
Symptoms of AR include rhinorrhea, nasal obstruction, sneezing, and nasal itching.3

While the complications of AR are not life-threatening, the condition, if left untreated, is
associated with impaired quality of life, decreased work performance, and the potential to
exacerbate other conditions such as sleep apnea, otitis media, chronic sinusitis, and
asthma.4
It is estimated that 82% of Americans with AR use antihistamines, with the
majority using SGAs due to their low side effect profile compared to the first generation
antihistamines, which are associated with increased sedation.5 Other therapeutic classes
and medications indicated for AR include: intranasal antihistamines, intranasal
corticosteroids, leukotriene pathway inhibitors, and ipratropium nasal solution.6,7
Intranasal corticosteroids are recommended over the other therapeutic classes that treat
AR due to their higher efficacy in clinical trials, but many patients prefer the oral versus
the intranasal route of administration for their medications, which is why SGAs are more
commonly used.8
As policy, over-the-counter (OTC) SGAs were not covered in this health plan
population (cetirizine and loratadine products were available OTC prior to the study
period, while fexofenadine products became available OTC during the study period). The
decision not to cover prescription products within a therapeutic class that has OTC
products and the opportunity costs associated with such a decision are of interest to
employers and payers within the health insurance industry.9,10 The potential for higher
costs in drug spending exists if members are unwilling to purchase the OTC options outof-pocket and decide instead to seek brand-name prescription products in a different
therapeutic class. A 2004 North Carolina (NC) Medicaid study focused on the utilization
changes when loratadine (Claritin®) became available OTC and was no longer covered
in their population. It appeared that NC Medicaid recipients were 2.16 times more likely
to switch to a prescription-only SGA rather than use OTC loratadine.11 While these
results would indicate increased costs to plan sponsors that implemented a similar policy,
the landscape of allergic rhinitis medications has changed since the study on NC
Medicaid recipients results.
With the majority of SGAs available as OTC products in 2011, the policy was
extended to remove coverage of prescription-only SGAs (included desloratadine and
levocetirizine products) on January 1, 2012. This policy decision left health plan

participants who had been taking SGAs with three main options: purchase an OTC SGA,
such as loratadine, fexofenadine (Allegra®), or cetirizine (Zyrtec®); obtain a prescription
for an alternative medication, such as fluticasone propionate (Flonase®), mometasone
(Nasonex®) or montelukast (Singulair®); or leave their condition untreated. The purpose
of this study was to assess the utilization of SGAs and SGA alternatives and to assess the
rate of product switching associated with the coverage changes.
METHODS
Study Design
Pharmacy claim data from January 1, 2010 to October 31, 2012 were analyzed
using the Truven Health Advantage Suite® system. Three reference periods were
evaluated to assess utilization patterns: (1) a period during which desloratadine,
fexofenadine, and levocetirizine were covered, (2) a desloratadine and levocetirizine Rxonly coverage period during which fexofenadine OTC was introduced to the market, and
(3) an SGA non-coverage period.
[Insert Table 1 here]
Patient Population
Study participants had to be continuously enrolled in the managed care
organization and at least 18 years old. Subjects must have received ≥1 prescription for a
desloratadine, fexofenadine, or levocetirizine product during the study period.
Product Switching
Product switching was determined by having at least one new fill for a covered
SGA or SGA alternative (Appendix A) following the coverage change. Switches to an
SGA alternative within the same therapeutic class were not counted as a switch. For
example, if a health plan participant had one fill for mometasone before the coverage
change then had a fill for fluticasone propionate afterwards, this would not equal a
switch. The rate of product switching was calculated as the number of members who
switched per total number of users for the individual SGA users and total SGA users. In
order to determine the extent to which demographics were associated with medication
switching, chi-square and independent samples t-tests were run on gender and age,
respectively.

Fexofenadine switch determination:
Subjects must have had ≥1 fill for a fexofenadine product during the study period
and ≥1 new fill for desloratadine, levocetirizine, or SGA alternative following
discontinuation of fexofenadine coverage in order to be classified as a fexofenadine
switch user.
Desloratadine or levocetirizine switch determination:
Subjects must have had ≥1 fill for a desloratadine or levocetirizine product during
the study period and ≥1 fill for a new SGA alternative in 2012 in order to be classified as
a desloratadine or levocetirizine switch user.
[Insert Table 2 here]
RESULTS
During the study period, a total of 1,549 unique participants utilized fexofenadine,
desloratadine, and/or levocetirizine products. Only 15.4% of the study population had at
least one fill for a new medication after discontinuation of coverage (Table 2), while
6.8% of subjects were persistent in either filling the switched-to product or filling for a
medication within the same therapeutic class of the switched-to product.
[Insert Table 3 here]
54 study participants had fills for more than one of the SGAs. Of the 12% of
fexofenadine users that switched to desloratadine or levocetirizine, only 8% then
switched to a prescription SGA alternative in 2012.
The most common therapeutic class switched to was intranasal corticosteroids
(54%), followed by intranasal antihistamines (15%). A few switch users had the same fill
date for medications from separate therapeutic classes. Thus, they were classified as
combination therapy in Figure 1.
[Insert Figure 1 here]
There was increased utilization of intranasal corticosteroids (10.3%) between the
second quarters of 2010 and 2012, while the study population only grew by 8.3%. Annual
utilization of intranasal antihistamines and leukotriene pathway inhibitors stayed
relatively constant throughout the study period (Figure 2).
[Insert Figure 2 here]

No significant difference in switching rate was observed between genders, X2 (1, n
= 1,818) = .091, p = .763. Given that no violation of Levene’s Test for Homogeneity was
detected, a t-test assuming equal variances was run; no significant difference in age was
observed between the two groups either, t (1,818) = -.835, p = .404. From these tests we
inferred that gender and age did not influence medication switching behavior.
DISCUSSION
The majority of study participants (84.6%) taking SGAs did not switch to a
prescription SGA alternative following SGA coverage discontinuation. Furthermore, over
half of the members who switched to a prescription SGA alternative were not persistent
in filling the new medication, which could suggest that those health plan participants
purchased an OTC SGA or left their condition untreated.
For participants that bought OTC products after the policy change, there may be a
slight increase or decrease in medication cost shifting depending on the OTC product
selected and previous prescription SGA utilized. However, there is significant savings by
eliminating the need for a patient to go to a doctor’s office for a new prescription. Thus,
both the health plan and its members should see cost savings (unless the health plan
participant decided to leave the condition untreated). For those who switched to
prescription products, the medication cost would be the same or a little less (sometimes
inhalers last more than 30 days) because the same generic copayment would apply in
most cases. Additionally, health plan participants may have experienced a reduced impact
of allergies because the majority switched to the prescriber-preferred therapeutic class for
allergic rhinitis (inhaled corticosteroids).
The choice to switch to particular medication within a therapeutic class is often
correlated with the formulary status and the generic availability of the individual drug. If
a medication is not on the formulary, the health plan participant is less likely to utilize
that medication versus one that is on the formulary due to the increase in cost share.12
The formulary status can explain why the top three medications switched to were
fluticasone propionate (generic), mometasone (formulary brand), and montelukast
(formulary brand).

Limitations
Due to the retrospective nature of the observational study, it is impossible to be
certain if the SGA policy change caused a switch. A member could have coincidentally
stopped an SGA and started an alternative around the time of the policy change for a
variety of reasons, such as ineffectiveness in treating symptoms. Had this occurred, it
could have inflated the product switch rate. Another potential source of switch rate
inflation is that many of the SGA alternatives are also used to treat concomitant
conditions that AR patients are likely to experience, such as asthma.8 The persistence to
an SGA prior to the switch was not evaluated partly because of the seasonal nature of
AR, but mainly in order to not eliminate any health plan participants that may have been
impacted by the discontinuation of coverage. Thus, it is possible that a member with only
one fill for an SGA was counted as a product switcher. This happened in rare instances
but the reasoning behind a switch would be difficult to determine without contacting the
health plan participant or prescriber.
Another limitation is that medical claims were not utilized to determine the
diagnoses of the health plan participants. There is the potential for members to be taking
SGAs for chronic idiopathic urticaria, but the prevalence of this condition in the general
population is low at only 1%.13 The major downside of not using medical claims is that
all of the SGA alternatives are approved for conditions other than AR, such as asthma,
which could significantly increase the switch rate. An increase in switch rate could be
observed if a health plan participant was prescribed an intranasal corticosteroid for
asthma after the policy change even though the participant began purchasing an OTC
SGA for the treatment of AR.
It should be noted that different fexofenadine products went OTC at different
times between March-August 2011, which could influence the therapeutic class switched
to after the benefit change. For example, if a member received a 90-day supply of
fexofenadine plus pseudoephedrine in August 2011, it is highly unlikely the member
would receive a prescription for one of the remaining prescription SGA products before
January 1, 2012.
The financial impact of the discontinuation of SGA coverage was not assessed
because it was not possible to determine the rate of absenteeism and presenteeism in the

health plan population before, during and after the study period. In the United States,
approximately 4 million days of lost productivity at work and school are due to AR each
year.6 Because 84.6% of subjects did not have any claims for SGA alternatives, the
potential that some members left their AR untreated exists, which would negate the
money saved for the managed care health plan population.
CONCLUSION
The policy decision to discontinue coverage of second generation antihistamines
was not associated with seeking a prescription alternative by the majority of plan
members. Organizations within the health insurance industry can utilize the findings of
this study when considering coverage of over-the-counter (OTC) medications, taking into
account the limitations noted. With the potential for more medications to go OTC, this
observational study illustrates that managed care organizations can efficiently manage
drug costs for a fixed population by reserving scarce plan resources through appropriate
benefit design management.
This study contributes to the overall value to public health by highlighting how
people can be responsible for their own health management. One of the intentions of
health care reform is to empower the population to be educated health care consumers.
Rather than depending on a prescription from a health care provider, a patient can
determine which OTC product will be the most cost-effective option to treat their
condition. This process can be assisted with (or without) the help of the pharmacist on
duty at no cost to the patient. Additionally, those health plan participants impacted by the
policy that switched to intranasal corticosteroids may have improved control over their
symptoms, which would reduce the absenteeism/presenteeism for the managed care
organization’s population.

TABLES AND FIGURES
Table 1. Demographics
Characteristic
Age (years)
Female (%)

SGA users
(n=1,549)
42.2
63.8

Table 2. SGA Alternatives
Medication Class
Intranasal Corticosteroids
Leukotriene Pathway Inhibitors
Intranasal Antihistamines
Other

Generic Name
beclomethasone, budesonide, ciclesonide,
flunisolide, fluticasone propionate, fluticasone
furoate, mometasone, triamcinolone
montelukast, zafirlukast
azelastine, olopatadine
ipratropium nasal solution

Table 3. Medication Switch Rates After Benefit Change
≥ 1 Fill for
Alternative

≥ 2 Fills for
Alternative

Desloratadine (79)

11.4%

6.3%

Fexofenadine (1,392)

15.9%

6.8%

Levocetirizine (135)

10.4%

4.4%

Total Unique Users
(1,549)*

15.4%

6.8%

Second Generation
Antihistamine (n)

*54 users were noted as having used two or more SGAs

Figure 1. Therapeutic Class Switched to After Benefit Change
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Figure 2. Quarterly Utilization Patterns of SGAs and SGA Alternatives
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Appendix A Two variables were used: (1) Generic names (Red Book description of the generic
product); and Adjustment Type Medstat = non-adjusted (Medstat Advantage Suite
standard description for the type of adjustment for the claim)


Second Generation Antihistamines (SGAs):
o Desloratadine
o Desloratadine/Pseudoephedrine Sulfate
o Fexofenadine HCl/PSE HCl
o Fexofenadine hydrochloride
o Levocetirizine dihydrochloride



SGA replacements:
o Azelastine Hydrochloride
o Azelastine Hydrochloride/Fluticasone Propionate
o Beclomethasone Dipropionate
o Beclomethasone Dipropionate Monohydrate
o Beclomethasone Dipropionate, Micronized
o Ciclesonide
o Flunisolide
o Flunisolide, Micronized
o Fluticasone Furoate
o Fluticasone Propionate
o Ipratropium Bromide
o Mometasone Furoate
o Montelukast Sodium
o Olopatadine Hydrochloride
o Triamcinolone
o Triamcinolone, Micronized
o Zafirlukast
o Zileuton
o Budesonide/Formoterol Fumarate
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